Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Kite Pharma Details CAR-T Therapy Launch, Floats Pricing Benchmarks

Executive Summary

Kite plans to initially target 72 clinical institutions experienced with CAR-T for its KTE-C19 launch, including 10 from the get-go.


Related Content

Cell Design Labs Envisions Robot Control of Tomorrow's CAR-T Therapies
New Interim CAR-T Data Support Kite’s BLA Submission Plans
J.P. Morgan Notebook Day 4: Kite, Cellectis and MannKind
J.P. Morgan Notebook, Jan. 15: Kite, Vivus, Amarin
J.P. Morgan Notebook, Jan. 14: AbbVie, AstraZeneca, Juno & Bluebird


Related Companies